COMMUNIQUÉS West-GlobeNewswire

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
19/10/2026
Groundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups 86% of patients remained off all topical IOP-lowering drops 90% of patients maintained ≥20/25 [...]
Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology
19/10/2026
Company Continues to Advance Global Regulatory Strategy While Supporting U.S. Commercial Expansion NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or [...]
GuideAI Health Enters Clinical Study and Software Pilot Agreement with Boone Heart Institute
19/10/2026
Collaboration aims to evaluate AI-assisted lower extremity CT angiography and pilot GuideAI's Elevate platform in a preventive cardiology setting BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (Cboe CA: [...]
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
19/10/2026
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage [...]
Nyxoah Annonce ses Résultats Préliminaires pour le Troisième Trimestre 2026 et Ajuste ses Prévisions de Chiffre d’Affaires pour 2026
19/10/2026
INFORMATIONS RÉGLEMENTÉES INFORMATIONS PRIVILÉGIÉES Nyxoah Annonce ses Résultats Préliminaires pour le Troisième Trimestre 2026 et Ajuste ses Prévisions de Chiffre d’Affaires pour 2026 Le chiffre d’affaires net aux [...]
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
19/10/2026
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 U.S. net revenue grows 29% sequentially, driving third quarter global [...]
argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
19/10/2026
Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DM Patient [...]
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
19/10/2026
NEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative [...]
Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System
19/10/2026
Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple [...]
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
19/10/2026
Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trial Workforce reduced by approximately 60%; management and CEO salaries reduced Plan designed to substantially reduce [...]
Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula
19/10/2026
New TREMFYA ® (guselkumab) 3-year as-observed data show clinical remission rates of up to 94% (172/183 patients) and endoscopic remission rates of up to 52% (89/172 patients) in adults with moderate to severe Crohn’s [...]
Decamen App Launches Personalized Military-Style Home Workout Plan for Busy Men
19/10/2026
New App Turns a Short Quiz Into a Personalized Training Plan, Meal Plan, and Coach Chat NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Decamen has launched a performance and wellness app for men built around military-style [...]
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
19/10/2026
- Largest Shareholder Increases Position as Dogwood Advances Halneuron ® Toward Topline Phase 2b Data Readout in November 2026 - - Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory [...]
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
19/10/2026
- FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis - - Abstract authored by REGAIN study principal investigator Dr. Joshua Palmer of The Ohio [...]
J-Star Holding Co., Ltd. Advances U.S. Drone Manufacturing Initiative; Negotiates Acquisition of Facility in the Greater Houston Area
19/10/2026
Company is Organizing an Independent Texas-based Manufacturing Platform, Contributing Proprietary Composite Technology and Engineering Expertise to Support Planned U.S. Drone-Frame Production Strategic Real Estate [...]
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
19/10/2026
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Indivior to Report Third Quarter 2026 Financial Results
19/10/2026
RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will [...]
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
19/10/2026
ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
19/10/2026
In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with “Process Validation” required under FDA “Good Manufacturing [...]

Pages